NEW research has confirmed the importance of administering proton pump inhibitors (PPIs) concomitantly with warfarin or non-vitamin K oral anticoagulants (NOACs) such as rivaroxaban (Bayer's Xarelto), dabigatran (BI's Pradaxa) and apixaban (Pfizer's Eliquis).
Researchers from the Vanderbilt University School of Medicine investigated data relating to 1,643,123 patients with 1,713,183 new episodes of oral anticoagulant treatment included in the cohort and 1,161,989 person-years of follow-up.
Past studies have shown apixaban to be associated with the lowest rate of upper GI bleeding, while rivaroxaban and warfarin had the highest rates.
This study was said to be consistent with all previous data around these products and authors said the information should "inform assessment of risks and benefits when choosing anticoagulant agents".
See jamanetwork.com for more.
The above article was sent to subscribers in Pharmacy Daily's issue from 07 Dec 18
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 07 Dec 18
